These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 9579299)
1. The relationship between phenytoin pharmacokinetics and the CYP2C19 genotype in Japanese epileptic patients. Watanabe M; Iwahashi K; Kugoh T; Suwaki H Clin Neuropharmacol; 1998; 21(2):122-6. PubMed ID: 9579299 [TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Odani A; Hashimoto Y; Otsuki Y; Uwai Y; Hattori H; Furusho K; Inui K Clin Pharmacol Ther; 1997 Sep; 62(3):287-92. PubMed ID: 9333104 [TBL] [Abstract][Full Text] [Related]
3. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067 [TBL] [Abstract][Full Text] [Related]
4. Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using Non-linear Mixed Effects Model approach. Yukawa E; Mamiya K J Clin Pharm Ther; 2006 Jun; 31(3):275-82. PubMed ID: 16789993 [TBL] [Abstract][Full Text] [Related]
5. CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. Mamiya K; Hadama A; Yukawa E; Ieiri I; Otsubo K; Ninomiya H; Tashiro N; Higuchi S Eur J Clin Pharmacol; 2000; 55(11-12):821-5. PubMed ID: 10805060 [TBL] [Abstract][Full Text] [Related]
6. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population. He N; Yan FX; Huang SL; Wang W; Xiao ZS; Liu ZQ; Zhou HH Eur J Clin Pharmacol; 2002 Apr; 58(1):15-8. PubMed ID: 11956668 [TBL] [Abstract][Full Text] [Related]
7. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population. Sviri S; Shpizen S; Leitersdorf E; Levy M; Caraco Y Clin Pharmacol Ther; 1999 Mar; 65(3):275-82. PubMed ID: 10096259 [TBL] [Abstract][Full Text] [Related]
8. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Herrlin K; Massele AY; Jande M; Alm C; Tybring G; Abdi YA; Wennerholm A; Johansson I; Dahl ML; Bertilsson L; Gustafsson LL Clin Pharmacol Ther; 1998 Oct; 64(4):391-401. PubMed ID: 9797796 [TBL] [Abstract][Full Text] [Related]
9. A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype. Brøsen K; de Morais SM; Meyer UA; Goldstein JA Pharmacogenetics; 1995 Oct; 5(5):312-7. PubMed ID: 8563772 [TBL] [Abstract][Full Text] [Related]
10. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Persson I; Aklillu E; Rodrigues F; Bertilsson L; Ingelman-Sundberg M Pharmacogenetics; 1996 Dec; 6(6):521-6. PubMed ID: 9014201 [TBL] [Abstract][Full Text] [Related]
11. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms. Hung CC; Lin CJ; Chen CC; Chang CJ; Liou HH Ther Drug Monit; 2004 Oct; 26(5):534-40. PubMed ID: 15385837 [TBL] [Abstract][Full Text] [Related]
12. Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Hashimoto Y; Otsuki Y; Odani A; Takano M; Hattori H; Furusho K; Iui K Biol Pharm Bull; 1996 Aug; 19(8):1103-5. PubMed ID: 8874828 [TBL] [Abstract][Full Text] [Related]
13. Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting. Lee SY; Lee ST; Kim JW J Biochem Mol Biol; 2007 May; 40(3):448-52. PubMed ID: 17562299 [TBL] [Abstract][Full Text] [Related]
14. Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India. Rosemary J; Surendiran A; Rajan S; Shashindran CH; Adithan C Indian J Med Res; 2006 May; 123(5):665-70. PubMed ID: 16873909 [TBL] [Abstract][Full Text] [Related]
15. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. Xiao ZS; Goldstein JA; Xie HG; Blaisdell J; Wang W; Jiang CH; Yan FX; He N; Huang SL; Xu ZH; Zhou HH J Pharmacol Exp Ther; 1997 Apr; 281(1):604-9. PubMed ID: 9103550 [TBL] [Abstract][Full Text] [Related]
16. Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese. Takakubo F; Kuwano A; Kondo I Pharmacogenetics; 1996 Jun; 6(3):265-7. PubMed ID: 8807668 [TBL] [Abstract][Full Text] [Related]
17. Association of polymorphisms in the cytochrome P450 (CYP) 2C19 and 2C18 genes in Japanese epileptic patients. Mamiya K; Ieiri I; Miyahara S; Imai J; Furuumi H; Fukumaki Y; Ninomiya H; Tashiro N; Yamada H; Higuchi S Pharmacogenetics; 1998 Feb; 8(1):87-90. PubMed ID: 9511186 [No Abstract] [Full Text] [Related]
18. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype. Tanaka M; Ohkubo T; Otani K; Suzuki A; Kaneko S; Sugawara K; Ryokawa Y; Hakusui H; Yamamori S; Ishizaki T Clin Pharmacol Ther; 1997 Dec; 62(6):619-28. PubMed ID: 9433390 [TBL] [Abstract][Full Text] [Related]
19. [Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration]. Huang Y; Yang JF; Qi XL; Wang YQ; Wang WZ; Chen B Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(20):1686-9. PubMed ID: 15569425 [TBL] [Abstract][Full Text] [Related]
20. Phenytoin kinetics in Japanese adult epileptics: phenotype of phenytoin slow metabolizers. Watanabe M; Iwahashi K; Kugoh T; Suwaki H Clin Neuropharmacol; 1997 Aug; 20(4):346-51. PubMed ID: 9260732 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]